News and Insights of 3D Printing and Manufacturing
Microscale 3D printer manufacturer Boston Micro Fabrication is making its debut in the dental sector by launching UltraThineer, the “world’s thinnest cosmetic dental veneer.” This news follows right after the company secured $24 million in series D funding to advance micro-scale additive manufacturing.
Chinese drug 3D printing firm Triastek has concluded its First-in-Human (FIH) study of its new 3D printing drug, dubbed T21. This drug is designed to treat moderate to severe ulcerative colitis (UC).
Austrian ceramic 3D printing company Lithoz and New York-based biomaterials specialist Himed have announced a long-term partnership to drive innovation in the 3D printing of medical-grade bioceramics.
Amnovis, an additive manufacturing production and engineering company based in Belgium, has produced a United States Food and Drug Administration (FDA) Master File.
BiologIC Technologies, the UK based biotechnology company behind the 3D printed ‘lab-on-a-chip’ platform, has received funding from Innovate UK. This financial support has allowed the company to accelerate the development and manufacture of cheaper drugs and vaccines.
3D BioFibR, a Canadian tissue engineering company, is launching two new collagen fiber products, μCollaFibR and CollaFibR 3D scaffold, to enhance 3D bioprinting.
Four companies in the medical device manufacturing industry namely EOS, Precision ADM, Orthopaedic Innovation Centre (OIC), and Tecomet, have announced a partnership. This alliance will provide an end-to-end solution for medical device additive manufacturing.
Colorado-based med-tech company Mighty Oak Medical has announced a partnership with HP. This partnership will see Mighty Oak Medical using HPs Jet Fusion 5200 3D printers to develop 3D printed healthcare applications.
Since they launched last year, HP’s latest Jet Fusion 5420W and Metal Jet S100 systems have significantly expanded the medical 3D printing potential of its portfolio.
Stratasys and CollPlant have announced plans to “transform healthcare with industrial scale bioprinting of tissues and organs.” To establish a method for bio-fabricating human tissues and organs utilizing CollPlant Biotechnologies’ rh-Collagen-based bioinks and Stratasys Ltd’s P3 technology-based bioprinter, the two companies have signed a cooperative development and commercialization agreement. The first project focuses on making a solution for CollPlant’s program for regenerative breast implants that can be used on an industrial scale.